{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:16:56Z","timestamp":1789204616967,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Aage Bangs Fond"},{"name":"Ebba Celinders Legat"},{"name":"the Danish Psoriasis Foundation"},{"name":"the Kong Christian X fond"},{"name":"the LEO Fondet"},{"name":"the AP M\u00f8ller fonden"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>For people with psoriasis, biomarkers aiding in the personalization of treatment with biologics are needed. We examined the usefulness of several biomarkers of inflammation in this respect. The neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the systemic immune\u2013inflammation index (SII) were measured in patients with psoriasis initiating TNF-\u03b1 inhibitors (n = 131), IL-17\/IL-17R inhibitors (n = 65), or IL-23\/IL-12\/23 inhibitors (n = 50). The blood levels of tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2, interferon (IFN)-\u03b3, IL-17A, IL-6, soluble IL-6 receptor (sIL-6R), and soluble IL-6 signal transducer (sIL-6ST) were measured in patients initiating adalimumab (n = 62) or IL-17\/IL-17R inhibitors (n = 24). Treatment response was defined by a psoriasis area and severity index (PASI) \u2264 2 three months after treatment initiation. Responders to TNF-\u03b1 inhibitors had a lower NLR at baseline than non-responders (median and interquartile range (IQR) 2.15 (1.67\u20132.86) vs. 2.54 (1.88\u20133.55); p = 0.04). Responders to treatment with adalimumab had lower IL-6 levels at baseline than non-responders (0.99 (0.42\u20131.4) vs. 1.62 (0.96\u20132.41) pg\/mL; p = 0.02). For the majority of patients, the IL-17A, IL-1\u03b2, and IFN-\u03b3 levels were below quantification limits. NLR and IL-6 may serve as predictive biomarkers of treatment response to TNF-\u03b1 inhibitor therapy in patients with psoriasis.<\/jats:p>","DOI":"10.3390\/ijms24076111","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:50:21Z","timestamp":1679629821000},"page":"6111","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis"],"prefix":"10.3390","volume":"24","author":[{"given":"Clara Sophie Bramsen","family":"Andersen","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-9151","authenticated-orcid":false,"given":"Amanda","family":"Kvist-Hansen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Siewertsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Enevold","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-535X","authenticated-orcid":false,"given":"Peter Riis","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diljit","family":"Kaur-Knudsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5506-1319","authenticated-orcid":false,"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7543-9016","authenticated-orcid":false,"given":"Claus Henrik","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, 2200 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark"},{"name":"Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_3","unstructured":"Selskab, D.D. (2023, January 13). Guideline DDS 2. Generations Immunmodulatorisk Behandling Opdateret December 2021. Available online: https:\/\/dds.nu\/wp-content\/uploads\/2022\/03\/Guideline-DDS-2.-generations-immunomodulatorisk-behandling-opdateret-december-2021-opdatering-1.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of systemic treatment response in people with psoriasis: A scoping review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: Evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1111\/ajd.12760","article-title":"Baseline patients\u2019 characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments","volume":"59","author":"Xie","year":"2018","journal-title":"Australas. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/bjd.16776","article-title":"Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: A multicentre longitudinal cohort study","volume":"180","author":"Warren","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediat. Inflamm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/ijdvl.IJDVL_471_17","article-title":"Is there a correlation of serum and tissue T helper-1 and -2 cytokine profiles with psoriasis activity and severity? A cross-sectional study","volume":"84","author":"Khandpur","year":"2018","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10238-018-0538-x","article-title":"Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: A systematic review and meta-analysis","volume":"19","author":"Paliogiannis","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"ref_12","first-page":"352","article-title":"Systemic Immune-Inflammation Index (SII) Predicts Increased Severity in Psoriasis and Psoriatic Arthritis","volume":"46","author":"Yorulmaz","year":"2020","journal-title":"Curr. Health Sci. J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kvist-Hansen, A., Kaiser, H., Wang, X., Krakauer, M., G\u00f8rtz, P.M., McCauley, B.D., Zachariae, C., Becker, C., Hansen, P.R., and Skov, L. (2021). Neutrophil Pathways of Inflammation Characterize the Blood Transcriptomic Signature of Patients with Psoriasis and Cardiovascular Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910818"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jcct.2020.12.006","article-title":"Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study","volume":"15","author":"Dey","year":"2021","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21438","DOI":"10.1038\/s41598-021-00999-9","article-title":"Biomarkers of subclinical atherosclerosis in patients with psoriasis","volume":"11","author":"Kaiser","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: Analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5114\/ada.2020.94838","article-title":"The effect of biological agent treatment on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, and C-reactive protein in psoriasis patients","volume":"37","author":"An","year":"2020","journal-title":"Adv. Dermatol. Allergol. Dermatol. I Alergol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/1346-8138.13875","article-title":"Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics","volume":"44","author":"Asahina","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5021\/ad.2019.31.6.601","article-title":"The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio","volume":"31","author":"Karabay","year":"2019","journal-title":"Ann. Dermatol."},{"key":"ref_20","first-page":"adv00568","article-title":"Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveals Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12\/23 Antagonists","volume":"101","author":"Hoffmann","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-019-04276-x","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-\u03b1 agents in patients with rheumatoid arthritis: A retrospective chart review analysis","volume":"39","author":"Lee","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"adv00357","DOI":"10.2340\/00015555-3722","article-title":"Response to Biologics During the First Six Months of Therapy in Biologic-na\u00efve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study","volume":"101","author":"Loft","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e15106","DOI":"10.1111\/dth.15106","article-title":"Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis","volume":"34","author":"Loft","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.4049\/jimmunol.0901017","article-title":"Protumor vs antitumor functions of IL-17","volume":"183","author":"Murugaiyan","year":"2009","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fimmu.2019.00382","article-title":"Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses","volume":"10","author":"Menegatti","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: Designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/09546634.2014.880396","article-title":"Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper","volume":"26","author":"Girolomoni","year":"2015","journal-title":"J. Dermatolog. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.29271\/jcpsp.2022.06.773","article-title":"Systemic Immune Inflammation Index as a Reliable Disease Activity Marker in Psoriatic Arthritis","volume":"32","author":"Dincer","year":"2022","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: Defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6111\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:58Z","timestamp":1760122918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076111"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076111","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}